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PXPEDITED REVIEWS
atent Foramen Ovale: Innocent or Guilty?
vidence From a Prospective Population-Based Study
rene Meissner, MD,* Bijoy K. Khandheria, MD,† John A. Heit, MD,* George W. Petty, MD,*
heldon G. Sheps, MD,‡ Gary L. Schwartz, MD,‡ Jack P. Whisnant, MD,§ David O. Wiebers, MD,*
ody L. Covalt,¶ Tanya M. Petterson, Teresa J. H. Christianson, Yoram Agmon, MD*
ochester, Minnesota
OBJECTIVES We sought to determine the association between patent foramen ovale (PFO), atrial septal
aneurysm (ASA), and stroke prospectively in a unselected population sample.
BACKGROUND The disputed relationship between PFO and stroke reflects methodologic weaknesses in
studies using invalid controls, unblinded transesophageal echocardiography examinations, and
data that are unadjusted for age or comorbidity.
METHODS The use of transesophageal echocardiography to identify PFO was performed by a single
echocardiographer using standardized definitions in 585 randomly sampled, Olmsted County
(Minnesota) subjects age 45 years or older participating in the Stroke Prevention: Assessment
of Risk in a Community (SPARC) study.
RESULTS A PFO was identified in 140 (24.3%) subjects and ASA in 11 (1.9%) subjects. Of the 140
subjects with PFO, 6 (4.3%) had an ASA; of the 437 subjects without PFO, 5 had an ASA
(1.1%, two-sided Fisher exact test, p  0.028). During a median follow-up of 5.1 years,
cerebrovascular events (cerebrovascular disease-related death, ischemic stroke, transient
ischemic attack) occurred in 41 subjects. After adjustment for age and comorbidity, PFO was
not a significant independent predictor of stroke (hazard ratio 1.46, 95% confidence interval
0.74 to 2.88, p  0.28). The risk of a cerebrovascular event among subjects with ASA was
nearly four times higher than that in those without ASA (hazard ratio 3.72, 95% confidence
interval 0.88 to 15.71, p  0.074).
CONCLUSIONS These prospective population-based data suggest that, after correction for age and comor-
bidity, PFO is not an independent risk factor for future cerebrovascular events in the general
population. A larger study is required to test the putative stroke risk associated with
ASA. (J Am Coll Cardiol 2006;47:440–5) © 2006 by the American College of Cardiology




















phe relationship between paradoxical (right-to-left) embo-
ism from a patent foramen ovale (PFO) and stroke remains
ontroversial despite numerous studies implicating this con-
ition with the risk of stroke. Methodologic weaknesses
riving the lack of conclusive results in published data
See page 446
nclude the retrospective, circumstantial, and anecdotal
ature of analyses; poor selection of controls; and, impor-
antly, data that are unadjusted for age and comorbidity (1).
ardiac embolism causes an estimated one-fifth of ischemic
trokes (2), 60,000 to 110,000 of which result from PFO
ccording to some accounts (1,3,4). The variability in
eported stroke risk from PFO ranges from 1% (5,6) to as
igh as 17.5% (7). These figures underscore the magnitude
f this controversy.
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S-06663 from the National Institute of Neurological Disorders and Stroke.s
Manuscript received July 28, 2005; revised manuscript received September 26,
005, accepted October 3, 2005.The Stroke Prevention: Assessment of Risk in a Com-
unity (SPARC) study was designed to estimate the
revalence of potential risk factors for stroke in the popu-
ation. The prevalence of PFO was found to be 25.6% (8),
hich is consistent with autopsy reports of the frequency of
FO in patients with normal hearts (3,9,10). This high
revalence of PFO in combination with considerable en-
husiasm for PFO closure, as a result of the recent advent of
atheter-closure devices, creates a pressing need for prospec-
ive, methodologically sound data regarding the long-term
isk of PFO. The SPARC study we describe is the largest
ransesophageal echocardiography (TEE)-based study of
troke outcome in a random sample of the population.
ETHODS
atient population. The resources of the Rochester Epi-
emiology Project in Rochester, Minnesota, were used to
numerate and randomly sample the entire 45-years-or-
lder Olmsted County population. These study subjects
ere not volunteers. The study design and initial results of
he first phase of the SPARC study have been published
reviously (8,11). An age- and gender-stratified random
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January 17, 2006:440–5 Patent Foramen Ovale,475 residents were chosen, of whom 230 were ineligible
y predetermined exclusion criteria (terminal illness, de-
entia precluding informed consent, severe disability, or
sophageal disease precluding TEE), and 657 declined to
articipate. The final SPARC study sample consisted of 588
andomly sampled subjects (approximately one-half of those
ligible) who consented to multimodality testing, including
edical record review, home medical interview, TEE,
arotid ultrasonography, and repeated blood pressure mea-
urements. A comparison of comorbid conditions, age, and
ender among participants and a random sample of eligible
on-participants (decliners) showed no significant differ-
nces, thus confirming that participants were a representa-
ive sample of the population (11). This prospective
ollow-up study was approved by the Mayo Foundation
nstitutional Review Board.
End point definitions were specified before initiation of
he study, and updated information was obtained from the
edical records of the subjects five years after the original
PARC study assessment. Three of the 588 subjects de-
lined authorization for medical research under Minnesota
tatute 144.335. Baseline data collected for these three
ubjects indicated that none had PFO; one had atrial septal
neurysm (ASA). Of the 585 subjects available for follow-
p, 8 were missing PFO assessment (7 had unsuccessful
EE and 1 was uncooperative for the cough and Valsalva
aneuvers). TEE was successful in 577 subjects.
EE. Baseline transthoracic echocardiography and multi-
lane TEE (12) were conducted according to standard
ractice guidelines with commercially available ultrasono-
raphic instruments (8,13). The heart and thoracic aorta
ere scanned for the presence of potential embolism sources
14). The interatrial septum (IAS) was viewed primarily in
he transverse midesophageal four-chamber view and the
ongitudinal biatrial-bicaval view. All TEEs were reviewed
ystematically by a cardiologist who was blinded to the
ubject’s comorbid history.
chocardiographic definitions. PATENT FORAMEN OVALE. A
FO was defined as a right-to-left interatrial shunt diag-
osed with intravenous injections of agitated saline while
he patient was at rest and with provocative maneuvers
cough or release of Valsalva or both). The PFO grade was
ichotomized as maximal shunting 10 versus 10 bub-
les. Visualization of a “hole” only was not sufficient for this
Abbreviations and Acronyms
ASA  atrial septal aneurysm
CVD  cerebrovascular events
IAS  interatrial septum
PFO  patent foramen ovale
SPARC  Stroke Prevention: Assessment of Risk in a
Community study
TEE  transesophageal echocardiography
VTE  venous thromboembolismnalysis. mSA. We defined ASA according to criteria previously
ublished by Agmon et al. (13) and Hanley et al. (15): 1)
iameter of the base of the aneurismal portion of the IAS 15
m or more and either 2) protrusion of the IAS, or part of
t, 15 mm or more beyond the plane of the IAS or 3) phasic
xcursion of the IAS during the cardiorespiratory cycle 15
m or more in total amplitude.
TE. The data resources of the Rochester Epidemiology
roject (16) were used to identify the inception cohort of
esidents of Olmsted County, Minnesota, with a first
ifetime deep venous thrombosis, pulmonary embolism, or
hronic thromboembolic pulmonary hypertension during
he 30-year period 1966 through 1995. Consistent criteria
ere used to identify venous thromboembolism (VTE) (17).
nly those incident VTEs occurring before entry into the
PARC study were considered as contributing to the
aseline risk of cerebrovascular events.
ND POINT. Cerebrovascular events (CVDs) were transient
schemic attack, cerebral infarct, or death (either primary or
ontributing cause) as the result of the aforementioned
onditions.
tatistical analysis. Survival free of CVDs was estimated
ith the Kaplan-Meier product-limit method, starting at
he initial SPARC visit. Subjects were censored at the last
edical visit if they were lost to follow-up (two subjects), at
he date of the medical record abstraction, or at the date of
eath if not due to CVD. Univariate Cox proportional
azards regression analyses unadjusted, adjusted for age and
ale gender and adjusted for previously derived risk factors
previous myocardial infarction, atrial fibrillation, age, and
ender), were used to determine the effect of PFO, ASA,
nd VTE on CVD. An exploratory stepwise Cox propor-
ional hazards regression model included age and gender.
ll other baseline variables were allowed to compete,
ncluding previous myocardial infarction, atrial fibrillation,
FO, ASA, VTE, and the remaining variables listed in
able 1. A p value of 0.05 was used to determine whether
variable would enter or leave the model. A follow-up
nalysis was done in which a p value of 0.10 was used to
etermine whether a variable would enter or leave the
odel. All two-way interactions between all variables in the
nal stepwise model were explored whenever sample size
as sufficient. The proportional hazards assumption was
xamined for the final stepwise multivariate risk factor
odel. The proportional hazards assumption is invalid if the
atio of the hazards depends on time.
ESULTS
orty-one subjects had a qualifying stroke. Fifty-one sub-
ects died before having CVD and were censored because of
eath. Of the 585 subjects, 493 (84.3%) were alive at the
ensor date. Patent foramen ovale was found in 140 of 577
ubjects (24.3%); 8 subjects were missing the PFO measure-
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Patent Foramen Ovale January 17, 2006:440–5isualization only. Eleven subjects had an ASA. Of the 140
ubjects with PFO, 6 (4.3%) had an ASA; of the 437
ubjects without PFO, 5 (1.1%) had an ASA (two-sided
isher exact test, p  0.028). A total of 12 subjects had a
revious VTE: 6 had a PFO, 5 did not have a PFO, and 1
as missing the PFO measurement (uncooperative for
ough and Valsalva maneuvers) (Table 2).
Of the 140 subjects with PFO, 12 had a cerebrovascular
schemic event at follow-up; none of the 12 subjects had
ssociated ASA. The Kaplan-Meier estimate of survival free
f CVD at five years was 91% for subjects with PFO and
3% for those without PFO (Fig. 1). Patent foramen ovale
as not associated with an increase in the hazard of CVD in
ny of the models (all p values  0.25) (Table 3). No
nteractions between PFO and any of the adjusting variables
able 1. Frequency of Atherosclerosis Risk Factors, Previous
ardiac or Cerebrovascular Disease, and Patent Foramen Ovale,





ge, yrs 66.9  13.3
ale gender 293 (50.1)
ody mass index, kg/m2 26.9  5.1
lood pressure
Systolic, mm Hg 137.6  19.7
Diastolic, mm Hg 79.7  9.7
Pulse pressure, mm Hg 57.8  18.1
Hypertension* 323 (55.2)
moking history (ever) 276 (47.2)
Past 228 (39.0)
Current 48 (8.2)
iabetes mellitus 52 (8.9)
ipid-lowering drug therapy 50 (8.5)
revious cardiac events (before SPARC)
Myocardial infarction 43 (7.4)
Angina pectoris 67 (11.5)
Coronary revascularization† 39 (6.7)
Coronary artery disease‡ 80 (13.7)
Congestive heart failure§ 25 (4.3)
Atrial fibrillation or flutter 41 (7.0)
revious cerebrovascular events or procedures
(before SPARC)
Ischemic stroke 22 (3.8)
Transient ischemic attack 17 (2.9)
Carotid endarterectomy 6 (1.0)
Cerebrovascular disease 37 (6.3)
ortic plaques (any) (n  579) 297 (51.3)
Simple 253 (43.7)
Complex 44 (7.6)
atent foramen ovale (n  577) 140 (24.3)
Maximal shunting 10 bubbles 63 (10.9)
trial septal aneurysm 11 (1.9)
enous thromboembolism 12 (2.1)
Defined as blood pressure 140/90 mm Hg or more or subject receiving antihyper-
ensive drug therapy or both. †Coronary artery bypass operation or percutaneous
oronary intervention. ‡Defined as a history of myocardial infarction, angina pectoris,
r coronary revascularization. §Congestive heart failure related to atherosclerotic
isease. Defined as a history of ischemic stroke, transient ischemic attack, or carotid
ndarterectomy.
SPARC  Stroke Prevention: Assessment of Risk in a Community.ere statistically significant. Although the hazard ratios
F
iere slightly more than 1.0 (range, 1.27 to 1.46), the 95%
onfidence intervals were wide and contained 1.0. Further-
ore, PFO grade (Table 1) was not related to CVD in the
nivariate and multivariate analyses adjusted for age, gen-
er, and other risk factors (all p values  0.75).
The Kaplan-Meier estimate of survival free of CVD at
ve years was 81% for those with ASA and 93% for those
ithout ASA (Fig. 2). Atrial septal aneurysm was strongly,
ut not significantly, associated with an increase in the
azard of CVD. The hazard of CVD in subjects with ASA
as nearly three times higher than the hazard in those
ithout ASA in the unadjusted model and the model
djusting for age and gender (p  0.16), although only 2 of
he 41 subjects with subsequent CVD had ASA; neither
ad associated PFO. After adjustment for age, gender, and
linical risk factors, the hazard was nearly four times higher
hazard ratio 3.72, 95% confidence interval 0.88 to 15.71,
 0.07) (Table 3).
The Kaplan-Meier estimate of survival free of CVD at
our years was 83% for subjects with VTE and 93% for those
ithout VTE (Fig. 3). Venous thromboembolism was not
ssociated with an increase in the hazard of CVD (all p 
.20) (Table 3). Estimates of the hazard ratio varied widely
0.77 to 2.52 for the completely adjusted and unadjusted
odels, respectively). No interactions between previous
TE and the adjusting variables were statistically significant
all p  0.30).
able 2. Frequency of Atrial Septal Aneurysm and Venous











resent 6 6 128 140
bsent 5 5 427 437
issing data* 0 1 7 8
otal 11 12 562 585
No data available because transesophageal echocardiography was unsuccessful.
ASA  atrial septal aneurysm; PFO  patent foramen ovale; VTE  venous
hromboembolism.igure 1. Kaplan-Meier estimate of survival free of cerebrovascular events
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January 17, 2006:440–5 Patent Foramen OvaleResults from both stepwise models are shown in Table 4.
s in previously reported analyses (18), when the p value to
nter and leave was set to 0.05, previous myocardial infarc-
ion and previous atrial fibrillation were the only variables to
nter the model after age and gender were included. When
he p value to enter and leave was set at 0.10, ASA and a
istory of diabetes entered the model, in addition to
revious myocardial infarction and atrial fibrillation, and
ere marginally significant.
ISCUSSION
n this population-based study, a detailed analysis of mul-
iple variables found that PFO is a highly prevalent condi-
ion (24.3%). After adjustment for age and risk factors, PFO
as not an independent predictor of CVD. More subjects
ith a PFO had an ASA (4%) than did subjects without a
FO (1%, p  0.03), but having a PFO was not signifi-
antly associated with an increase in the risk of a cerebro-
ascular end point.
A previous incident of VTE also was not significantly
ssociated with an increase in CVD. The association be-
ween ASA and CVD is less clear. Only 11 subjects had an
SA, 2 of whom had a cerebral ischemic event; hence, the
stimated increased risk was nearly four-fold. However,
espite the small numbers, this association is consistent
nivariately and after risk-factor adjustment, a suggestion
hat it is not spurious. Given the small number of strokes in
his population and the even smaller number of subjects
ith ASA, clearly a larger study is needed to test for an
ssociation between ASA and subsequent stroke (19).
able 3. Univariate Unadjusted and Adjusted Cox Proportional H
Variable
Unadjusted Adjust
Hazard Ratio 95% CI p Value Hazard Rat
PFO 1.28 0.65–2.50 0.48 1.27
ASA 2.98 0.72–12.35 0.13 2.80
VTE 2.52 0.61–10.45 0.20 1.96
Prior myocardial infarction and atrial fibrillation. See Table 4.
ASA  atrial septal aneurysm; CI  confidence interval; PFO  patent foramenF
i
igure 2. Kaplan-Meier estimate of survival free of cerebrovascular events
n 585 subjects according to presence of atrial septal aneurysm (ASA).Why the difference between results from the SPARC
tudy and the literature? Review of the PFO detection rates
eported in the literature show wide variability, suggesting
n underestimation of PFO in patients with stroke of
nown cause and an overdetection rate in tertiary referral
enters where nonincident, recurrent strokes are evaluated
20–25). This presumption is supported by a recent Mayo
linic study that compared patients undergoing TEE for
oncryptogenic stroke with those referred for cryptogenic
troke. The frequency of PFO was lowest in patients with
ardioembolic stroke at 10.5%, a finding suggesting that the
nblinding of echocardiographers to mechanisms of stroke
t the time of TEE (e.g., atrial fibrillation, valvular disease,
entricular thrombus) may have resulted in lower intensity
fforts to search for PFO. A comparison of contrast injec-
ions between controls and patients also supported an
nderdiagnosis of PFO in patients with known causes of
troke. Cardiac disorders in which left atrial pressures are
ncreased also may limit the sensitivity of contrast echocar-
iography for detecting right-to-left shunting (19).
Reported detection rates for patients referred for crypto-
enic stroke approach 50%, whereas the rates are low for
atients with stroke of known cause (Fig. 4). The combi-
ation of overdetection of PFO in referred cases of crypto-
enic stroke and underdiagnosis of PFO in patients with
nown causes of stroke may result in an overestimation of
he reported hazard ratios for cryptogenic stroke associated
ith PFO. The similar detection rates of PFO in a random
opulation sample and in population-based cases of crypto-
enic stroke challenge the popular opinion that PFO is
d Models of Cerebrovascular Events
r Age and Gender Adjusted for Multivariable Model*
95% CI p Value Hazard Ratio 95% CI p Value
0.65–2.50 0.48 1.46 0.74–2.88 0.28
0.67–11.64 0.16 3.72 0.88–15.71 0.07
0.47–8.11 0.36 0.77 0.18–3.36 0.73
; VTE  venous thromboembolism.azar
ed fo
ioigure 3. Kaplan-Meier estimate of survival free of cerebrovascular events
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Patent Foramen Ovale January 17, 2006:440–5ecessary and causal for stroke occurrence. The prospective,
opulation-based, random subject selection design of this
tudy obviates the biases in a study evaluating cause and
ffect once the end point has already occurred. This study is
nique in that it is the largest prospective randomly selected,
opulation-based TEE study to date. However, there were
elatively few cerebrovascular events, a factor potentially
imiting the ability for this study to detect a statistically
ignificant hazard. The 95% confidence interval for PFO
ndicates that the hazard ratio could be as low as 0.65 or as
igh as 2.5 and still be consistent with this study’s conclu-
ions. However, the hazard ratio estimate for PFO was very
odest (1.28), did not change after adjusting for age and
ender, and increased only slightly after additionally adjust-
ng for myocardial infarction and atrial fibrillation—
ndings suggesting that this result would hold true with
ore cerebrovascular events, even if the 95% confidence
nterval narrowed with a larger sample size. These are the
isks for the population as a whole; in an individual patient,
FO may be associated with an embolic cerebrovascular
vent.
ONCLUSIONS
atent foramen ovale is a common occurrence, occurring in
ne in four subjects in the population. Because of method-
logic inconsistencies, detection rates of PFO in different
opulations vary widely, leading to potentially inaccurate
able 4. Final Results of Two Stepwise Cox Proportional Hazard
Variable
p Value to Enter  0.05
Hazard Ratio 95% CI
ge† 1.70 1.29–2.23
ale 1.00 0.53–1.91
yocardial infarction 4.33 2.11–8.87
trial fibrillation/flutter 2.70 1.29–5.64
trial septal aneurysm
iabetes
Model previously described in Meissner et al. (18). †Per 10 years of age.
CI  confidence interval.
igure 4. Detection of patent foramen ovale (PFO) in different popula-
ions. Pop Cntrl  population-based randomly selected controls; Pop
rypto  population-based cryptogenic stroke; Ref Cntrl  referredontrol subjects/patients; Ref Crypto  referred cryptogenic stroke pa-
ients.onclusions regarding its association with stroke. Patent
oramen ovale does not seem to be an independent risk
actor for stroke in the general population. These data
hould provide guidance for management strategies for
atients with PFO, particularly those with comorbid car-
iovascular conditions. The stroke risk related to ASA is
ess clear and will require further follow-up of larger
opulation samples.
eprint requests and correspondence: Dr. Irene Meissner, De-
artment of Neurology, Mayo Clinic, 200 First Street SW,
ochester, Minnesota 55905. E-mail: meissner.irene@mayo.edu.
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